Newly Produced Peptides Eptifibatide Acetate for Adult with SGS

Eptifibatide is a specific inhibitor of fibrinogen binding to the platelet membrane integrin glycoprotein GPIIb/IIIa receptor, preventing platelet aggregation.
Eptifibatide (Integrilin, Millennium Pharmaceuticals, also co-promoted by Schering-Plough/Essex), is an antiplatelet drug of the glycoprotein IIb/IIIa inhibitor class. Eptifibatide is a cyclic heptapeptide derived from a protein found in the venom of the southeastern pygmy rattlesnake (Sistrurus miliarius barbouri). It belongs to the class of the arginin-glycin-aspartat-mimetics and reversibly binds to platelets. Eptifibatide has a short half-life. The drug is the third inhibitor of GPIIb/IIIa that has found broad acceptance after the specific antibody abciximab and the non-peptide tirofiban entered the global market.
Eptifibatide is used to reduce the risk of acute cardiac ischemic events (death and/or myocardial infarction) in patients with unstable angina or non-ST-segment-elevation (e.g., non-Q-wave) myocardial infarction (i.e., non-ST-segment elevation acute coronary syndromes) both in patients who are to receive non surgery (conservative) medical treatment and those undergoing percutaneous coronary intervention (PCI).

 

 

Our Company is the Peptides manufacturer,Specialized in :
1:Peptides(Bodybuilding Peptides,Research Peptides and Cosmetic Peptides)
2:Steroids(Raw powder,inject Oil,Tablets)
3:Amino Acid
4:Custom-made service

Packing

 

Laboratory

Freight

Eptifibatide is a specific inhibitor of fibrinogen binding to the platelet membrane integrin glycoprotein GPIIb/IIIa receptor, preventing platelet aggregation.
Eptifibatide (Integrilin, Millennium Pharmaceuticals, also co-promoted by Schering-Plough/Essex), is an antiplatelet drug of the glycoprotein IIb/IIIa inhibitor class. Eptifibatide is a cyclic heptapeptide derived from a protein found in the venom of the southeastern pygmy rattlesnake (Sistrurus miliarius barbouri). It belongs to the class of the arginin-glycin-aspartat-mimetics and reversibly binds to platelets. Eptifibatide has a short half-life. The drug is the third inhibitor of GPIIb/IIIa that has found broad acceptance after the specific antibody abciximab and the non-peptide tirofiban entered the global market.
Eptifibatide is used to reduce the risk of acute cardiac ischemic events (death and/or myocardial infarction) in patients with unstable angina or non-ST-segment-elevation (e.g., non-Q-wave) myocardial infarction (i.e., non-ST-segment elevation acute coronary syndromes) both in patients who are to receive non surgery (conservative) medical treatment and those undergoing percutaneous coronary intervention (PCI).

 

 

Our Company is the Peptides manufacturer,Specialized in :
1:Peptides(Bodybuilding Peptides,Research Peptides and Cosmetic Peptides)
2:Steroids(Raw powder,inject Oil,Tablets)
3:Amino Acid
4:Custom-made service

Packing

 

Laboratory

Freight